Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
JSPR Stock Forecast 2025-2026
$3.51
Current Price
$53.33M
Market Cap
Buy 11
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to JSPR Price Targets
+1,894.3%
To High Target of $70.00
+1,324.5%
To Median Target of $50.00
+327.4%
To Low Target of $15.00
JSPR Price Momentum
-48.2%
1 Week Change
-37.1%
1 Month Change
-81.6%
1 Year Change
-83.6%
Year-to-Date Change
-86.5%
From 52W High of $26.05
+55.0%
From 52W Low of $2.27
📊 TOP ANALYST CALLS
Did JSPR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Jasper is one of their latest high-conviction picks.
Latest JSPR Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, JSPR has a bullish consensus with a median price target of $50.00 (ranging from $15.00 to $70.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $3.51, the median forecast implies a 1,324.5% upside. This outlook is supported by 11 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Silvan Tuerkcan at JMP Securities, projecting a 1,894.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
JSPR Analyst Ratings
11
Buy
0
Hold
0
Sell
JSPR Price Target Range
Low
$15.00
Average
$50.00
High
$70.00
Current: $3.51
Latest JSPR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for JSPR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Maintains | $12.00 |
| Jul 8, 2025 | BMO Capital | Kostas Biliouris | Market Perform | Downgrade | $4.00 |
| Jul 8, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $20.00 |
| Jul 7, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Neutral | Downgrade | $0.00 |
| Jul 7, 2025 | William Blair | Matt Phipps | Market Perform | Downgrade | $0.00 |
| Jul 7, 2025 | BTIG | Justin Zelin | Buy | Maintains | $20.00 |
| Jul 7, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $20.00 |
| May 15, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $65.00 |
| May 13, 2025 | UBS | Trung Huynh | Buy | Maintains | $33.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $40.00 |
| Feb 13, 2025 | UBS | Trung Huynh | Buy | Initiates | $38.00 |
| Jan 10, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $70.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $40.00 |
| Jan 9, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $48.00 |
| Jan 6, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Maintains | $70.00 |
| Dec 23, 2024 | RBC Capital | Outperform | Reiterates | $0.00 | |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $63.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $65.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $65.00 |
| Oct 15, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $70.00 |
Jasper Therapeutics Inc. (JSPR) Competitors
The following stocks are similar to Jasper based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
JSPR
Jasper Therapeutics
mkt cap
53.33M
Jasper Therapeutics Inc. (JSPR) Financial Data
Jasper Therapeutics Inc. has a market capitalization of $53.33M with a P/E ratio of -0.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -101.3%.
Valuation Metrics
Market Cap
$53.33M
Enterprise Value
$37.16M
P/E Ratio
-0.7x
PEG Ratio
-0.8x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+92.5%
Current Ratio
4.3x
Debt/Equity
6.1x
ROE
-101.3%
ROA
-56.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Jasper Therapeutics Inc. (JSPR) Business Model
About Jasper Therapeutics Inc.
What They Do
Develops innovative therapies for disease treatment.
Business Model
The company operates by creating targeted technologies that enhance the safety and efficacy of therapies needed for hematopoietic cell transplantation and other immune-related disorders. It generates revenue through the development and commercialization of these innovative therapies aimed at improving patient outcomes, particularly in high-risk medical procedures like bone marrow transplants.
Additional Information
Jasper Therapeutics is strategically positioned in the biotechnology sector, with a strong focus on research and development that could lead to advancements in healthcare and transformative treatment options for patients with chronic immune disorders and autoimmune diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
64
CEO
Mr. Ronald A. Martell
Country
United States
IPO Year
2020
Website
jaspertx.comJasper Therapeutics Inc. (JSPR) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for investors of Jasper Therapeutics, Inc. (NASDAQ: JSPR). Interested parties should contact Danielle Peyton for more information.
Why It Matters
The investigation into Jasper Therapeutics may signal potential legal issues or financial misconduct, impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Jasper Therapeutics, Inc. ($JSPR) is under a fraud investigation, and investors have the opportunity to join this investigation through the Schall Law Firm.
Why It Matters
The potential fraud investigation into Jasper Therapeutics may indicate financial instability or legal risks, affecting stock value and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Jasper Therapeutics is reducing its workforce by 50% to focus on Chronic Urticaria programs and extend its cash runway. Dr. Daniel Adelman is appointed Acting Chief Medical Officer.
Why It Matters
Jasper Therapeutics' workforce reduction and leadership change signal a strategic shift to conserve cash and focus on key programs, impacting its growth potential and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Jasper Therapeutics, Inc. (JSPR) shares fell nearly 55% on Monday, with trading volume at 9.9 million, significantly higher than the average of 251.9K shares.
Why It Matters
Jasper Therapeutics' 55% stock drop and surge in trading volume signal potential panic selling, raising concerns about company performance and future prospects.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
In recent studies, 89% of participants in the 240mg and 360mg cohorts achieved complete responses, while 73% did in the 180mg Q8W extension. An asthma study is halted due to drug lot issues. No severe adverse events reported.
Why It Matters
Strong response rates in treatment cohorts indicate potential efficacy, but drug lot issues raise concerns about reliability. Upcoming call may provide clarity, impacting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
In a clinical trial, 92% of participants in the 180mg cohort achieved a complete response, with no serious adverse events reported. A conference call is scheduled for June 16 at 8:00 a.m. EDT.
Why It Matters
High response rates and no serious adverse events in the 180mg cohort indicate strong efficacy and safety for investors, potentially boosting stock value and market confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About JSPR Stock
What is Jasper Therapeutics Inc.'s (JSPR) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Jasper Therapeutics Inc. (JSPR) has a median price target of $50.00. The highest price target is $70.00 and the lowest is $15.00.
Is JSPR stock a good investment in 2026?
According to current analyst ratings, JSPR has 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for JSPR stock?
Wall Street analysts predict JSPR stock could reach $50.00 in the next 12 months. This represents a 1,324.5% increase from the current price of $3.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Jasper Therapeutics Inc.'s business model?
The company operates by creating targeted technologies that enhance the safety and efficacy of therapies needed for hematopoietic cell transplantation and other immune-related disorders. It generates revenue through the development and commercialization of these innovative therapies aimed at improving patient outcomes, particularly in high-risk medical procedures like bone marrow transplants.
What is the highest forecasted price for JSPR Jasper Therapeutics Inc.?
The highest price target for JSPR is $70.00 from Silvan Tuerkcan at JMP Securities, which represents a 1,894.3% increase from the current price of $3.51.
What is the lowest forecasted price for JSPR Jasper Therapeutics Inc.?
The lowest price target for JSPR is $15.00 from at , which represents a 327.4% increase from the current price of $3.51.
What is the overall JSPR consensus from analysts for Jasper Therapeutics Inc.?
The overall analyst consensus for JSPR is bullish. Out of 18 Wall Street analysts, 11 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $50.00.
How accurate are JSPR stock price projections?
Stock price projections, including those for Jasper Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 3:43 PM UTC